The Biomedical Prevention Program has 41 investigators from 16 departments and four schools with a research base of $6.8 million in annual direct funding, Including $4.4 million from the NCI. Its members published 1092 papers over this grant period, of which 37% were intra-programmatic and 39% ware interprogrammatic collaborations. 155 of these publications were in high impact journals (Impact factor >7.51). The objective of the Biomedical Prevention Program is to reduce the morbidity and mortality caused by cancer through preventing the occurrence and improving survival with earlier diagnosis. The alms of the program are: 1) To build and to support organ-focused, vertically Integrated research projects that encompass environmental and genetic approaches In order to Identify individuals and populations a high risk for future neoplastic progression;2) To discover and validate biomarkers for risk assessment and early detection of common, high mortality cancers through the integration of high throughput genomic, proteomic, and biotechnologies;3) To Identify and determine preventive efficacy of Interventions with pharmacologic and nutritional tools with the aim of delaying or reversing neoplastic progression in individuals identified at high risk;and 4) To develop and validate new biostatistical methodologies to study population clusters and surrogate endpoints. The populations targeted for these programs include the general population and special at-risk groups.

Public Health Relevance

All of the research in the Biomedical Prevention Program has direct cancer relevance and covers the spectrum of research Including basic pharmacology of chemopreventive agents, gene discovery and risk modeling, proteomic studies that are directly applied to early detection, pharmacologic interventions Including Phase II, investigator initiated trials of chemopreventive agents, pharmacogenetic studies of preventive agents and outcomestudies including biomarkers, survival and prevention of treatment symptoms.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Skolarus, Ted A; Metreger, Tabitha; Hwang, Soohyun et al. (2017) Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials 18:181
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Pinskey, Justine M; Franks, Nicole E; McMellen, Alexandra N et al. (2017) Neuropilin-1 promotes Hedgehog signaling through a novel cytoplasmic motif. J Biol Chem 292:15192-15204
Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341
Zhang, Jie; Feng, Shumei; Su, Wenmei et al. (2017) Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep 7:42819
Mann, J E; Hoesli, R; Michmerhuizen, N L et al. (2017) Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 8:332-344
Birkeland, Andrew C; Foltin, Susan K; Michmerhuizen, Nicole L et al. (2017) Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol 68:5-8
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Chen, Yan; Zhou, Quan; Li, Xue et al. (2017) Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. Bioconjug Chem 28:2794-2803

Showing the most recent 10 out of 1355 publications